Literature DB >> 7836949

Participation of the limbic system and its associated areas in the dementia of amyotrophic lateral sclerosis.

S Kato1, M Oda, H Hayashi, A Kawata, T Shimizu.   

Abstract

The topographic distribution of degenerative changes in large brain sections from five sporadic amyotrophic lateral sclerosis (ALS) patients with dementia and three without dementia was examined. The dementia characteristics were impaired shifting from one line of thinking to another, perseveration, and emotional disinhibition as well as impairment of cognition, and judgment. Neuropathological examinations showed definite ALS changes in all the patients studied. In addition, the five patients with dementia showed neuronal loss, gliosis, and sponginess of the superficial layers throughout the cerebral cortices, predominantly in the dorsomedial cortex of the temporal tip and the parahippocampal, ambiens, anterior cingulate, rectal, orbital, and insular gyri as well as neuronal loss in the basolateral nucleus of the amygdala, nucleus accumbens, and subiculum of the hippocampus. Ubiquitin-immunoreactive inclusions were present in some neurons in the granular cell layers of the hippocampus. Fibrous gliosis was extensive in the subcortical and deep white matter of the frontotemporal lobes. The affected regions take in the limbic system and its associated areas which are the sources of the psychological problems, including emotional disturbance, experienced by these ALS patients. The psychological problems of ALS need to be investigated in relation to the involvement of the limbic system.

Entities:  

Mesh:

Year:  1994        PMID: 7836949     DOI: 10.1016/0022-510x(94)90095-7

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  Relation between cognitive dysfunction and pseudobulbar palsy in amyotrophic lateral sclerosis.

Authors:  S Abrahams; L H Goldstein; A Al-Chalabi; A Pickering; R G Morris; R E Passingham; D J Brooks; P N Leigh
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-05       Impact factor: 10.154

Review 2.  The neuropathological signature of bulbar-onset ALS: A systematic review.

Authors:  S Shellikeri; V Karthikeyan; R Martino; S E Black; L Zinman; J Keith; Y Yunusova
Journal:  Neurosci Biobehav Rev       Date:  2017-02-02       Impact factor: 8.989

3.  Degeneration of the mid-cingulate cortex in amyotrophic lateral sclerosis detected in vivo with MR spectroscopy.

Authors:  N Sudharshan; C Hanstock; B Hui; T Pyra; W Johnston; S Kalra
Journal:  AJNR Am J Neuroradiol       Date:  2010-11-18       Impact factor: 3.825

4.  Cognitive function in bulbar- and spinal-onset amyotrophic lateral sclerosis. A longitudinal study in 52 patients.

Authors:  Herbert Schreiber; Tanja Gaigalat; Ursula Wiedemuth-Catrinescu; Michael Graf; Ingo Uttner; Rainer Muche; Albert Christian Ludolph
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

5.  Relation between cognitive dysfunction and reduced vital capacity in amyotrophic lateral sclerosis.

Authors:  S-M Kim; K-M Lee; Y-H Hong; K S Park; J-H Yang; H-W Nam; J-J Sung; K-W Lee
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-06-08       Impact factor: 10.154

6.  Amygdala size in amyotrophic lateral sclerosis without dementia: an in vivo study using MRI volumetry.

Authors:  Elmar H Pinkhardt; Ludger Tebartz van Elst; Albert C Ludolph; Jan Kassubek
Journal:  BMC Neurol       Date:  2006-12-25       Impact factor: 2.474

7.  Neuropathology of Speech Network Distinguishes Bulbar From Nonbulbar Amyotrophic Lateral Sclerosis.

Authors:  Sanjana Shellikeri; Julia Keith; Sandra E Black; Lorne Zinman; Yana Yunusova
Journal:  J Neuropathol Exp Neurol       Date:  2020-03-01       Impact factor: 3.685

8.  The Wobbler mouse model of amyotrophic lateral sclerosis (ALS) displays hippocampal hyperexcitability, and reduced number of interneurons, but no presynaptic vesicle release impairments.

Authors:  Karina D Thielsen; Jakob M Moser; Thomas Schmitt-John; Morten S Jensen; Kimmo Jensen; Mai Marie Holm
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.